Wall Street brokerages expect that Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) will post sales of $73.71 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Pacira Pharmaceuticals’ earnings. The highest sales estimate is $74.00 million and the lowest is $73.34 million. Pacira Pharmaceuticals reported sales of $68.36 million in the same quarter last year, which indicates a positive year-over-year growth rate of 7.8%. The firm is scheduled to issue its next earnings results on Wednesday, November 1st.

On average, analysts expect that Pacira Pharmaceuticals will report full year sales of $73.71 million for the current financial year, with estimates ranging from $292.00 million to $305.83 million. For the next fiscal year, analysts expect that the business will post sales of $385.78 million per share, with estimates ranging from $370.20 million to $415.60 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Pacira Pharmaceuticals.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.06. The firm had revenue of $70.90 million for the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.21 earnings per share.

A number of research firms recently issued reports on PCRX. Jefferies Group LLC reiterated a “buy” rating and set a $59.00 price objective on shares of Pacira Pharmaceuticals in a report on Thursday. CIBC started coverage on Pacira Pharmaceuticals in a research report on Thursday. They set a “market perform” rating for the company. Oppenheimer Holdings, Inc. started coverage on Pacira Pharmaceuticals in a research report on Thursday. They set a “market perform” rating for the company. UBS AG started coverage on Pacira Pharmaceuticals in a research report on Wednesday. They set a “market perform” rating for the company. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $54.00 price target on shares of Pacira Pharmaceuticals in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $52.92.

Shares of Pacira Pharmaceuticals (NASDAQ PCRX) opened at 37.10 on Friday. The stock’s 50 day moving average price is $38.04 and its 200 day moving average price is $44.70. The firm’s market capitalization is $1.50 billion. Pacira Pharmaceuticals has a one year low of $29.95 and a one year high of $58.95.

In other Pacira Pharmaceuticals news, CAO Kristen Marie Williams sold 3,461 shares of the firm’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total transaction of $127,191.75. Following the transaction, the chief accounting officer now owns 21,312 shares in the company, valued at approximately $783,216. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Paul J. Hastings sold 1,044 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total value of $37,740.60. Following the transaction, the director now owns 3,518 shares in the company, valued at approximately $127,175.70. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,390 shares of company stock valued at $1,215,480. 6.60% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the business. Oppenheimer Asset Management Inc. bought a new position in Pacira Pharmaceuticals during the 2nd quarter worth $114,000. Benjamin F. Edwards & Company Inc. increased its stake in Pacira Pharmaceuticals by 12.2% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock worth $133,000 after acquiring an additional 303 shares during the period. FNY Partners Fund LP bought a new position in Pacira Pharmaceuticals during the 1st quarter worth $136,000. Ameritas Investment Partners Inc. bought a new position in Pacira Pharmaceuticals during the 1st quarter worth $144,000. Finally, Cubist Systematic Strategies LLC increased its stake in Pacira Pharmaceuticals by 121.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock worth $152,000 after acquiring an additional 1,752 shares during the period.

TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate Pacira Pharmaceuticals, Inc. (PCRX) Will Announce Quarterly Sales of $73.71 Million” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/09/zacks-analysts-anticipate-pacira-pharmaceuticals-inc-pcrx-will-announce-quarterly-sales-of-73-71-million.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.